Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES W MIMS

Allopathic & Osteopathic Physicians Otolaryngology

NPI
1194709576
CMS profile
511210
Location
WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,701.98

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,685.00 1
Food and Beverage $16.98 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $2,685.00 1
Acclarent, Inc $14.17 1
Forte Bio-Pharma LLC $2.81 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES W MIMS

NPI 1194709576 · CMS profile ID 511210

Allopathic & Osteopathic Physicians / Otolaryngology

WINSTON SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194709576?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES W MIMS, NPI 1194709576, CMS profile ID 511210. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194709576?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JAMES W MIMS, NPI 1194709576, CMS profile ID 511210. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194709576?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JAMES W MIMS, NPI 1194709576, CMS profile ID 511210, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1194709576?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $2,701.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Forte Bio-Pharma LLC $2.8106/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796755251 CMS
AstraZeneca Pharmaceuticals LP $2,685.0005/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834335289 CMS
Acclarent, Inc $14.1703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787330113 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $2,701.98 3
PY2024 $7,094.36 7
PY2025 $5,354.91 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,799.15 2
PY2025 Principal investigator $6,496.89 35
PY2024 Recipient $1,359.30 4
PY2024 Principal investigator $17,871.04 32
PY2023 Principal investigator $58,196.86 135
PY2022 Principal investigator $16,157.94 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 12/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977204261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 11/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977197349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 11/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977195159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $269.57 10/19/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977189341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 10/19/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977189347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 10/19/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977189353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 10/19/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977189359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 10/19/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977189365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 10/02/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977183633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 10/02/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977183639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 10/02/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977183645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 09/04/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977180725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 08/04/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977175665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 08/04/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977175671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 07/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977165691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 07/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977159769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 07/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977159779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 07/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977159789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 07/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977159800
Principal investigator 1 GlaxoSmithKline, LLC. $4,480.00 06/27/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006245165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977134977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977134989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977134997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.00 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $153.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.00 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.00 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.00 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977135995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $153.60 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 06/14/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977136223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 06/05/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977114553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 06/05/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977114559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 06/05/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977114565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 06/05/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977114571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 05/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977109725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 05/10/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977108843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $736.13 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,044.86 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $707.33 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.37 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.00 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.92 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $44.80 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977099933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.60 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.28 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.16 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.52 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.12 03/17/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977100095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/03/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977095125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,800.00 03/01/2023 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY HEALTH SCIENCES
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 977094377